

Jubilant Prodel LLC
Balance Sheet as at 31 March 2025

		USD	USD
	Notes	As at 31 March 2025	As at 31 March 2024
ASSETS			
Non-current assets			
Intangible assets under development	3	7,565,968	7,520,280
Total non-current assets		7,565,968	7,520,280
Current assets			
Financial assets			
i. Cash and cash equivalents	4	381	3,959
Other current assets	5	220	1,740
Total current assets		601	5,699
Total assets		7,566,569	7,525,979
EQUITY AND LIABILITIES			
Equity			
Equity share capital	6	7,786,317	7,751,317
Other equity		(310,786)	(307,775)
Total Equity		7,475,531	7,443,541
LIABILITIES			
Current liabilities			
Financial liabilities			
i. Trade payables	7	91,038	82,438
Total current liabilities		91,038	82,438
Total liabilities		91,038	82,438
Total equity and liabilities		7,566,569	7,525,979



Shyam Pattabiraman
CFO

Place: New Jersey

Date: 12 May 2025

Syed Kazmi
CEO



Place: New Jersey

Date: 12 May 2025

Jubilant Prodel LLC
Statement of Profit and Loss for the year ended 31 March 2025

		USD	USD
	Notes	For the year ended 31 March 2025	For the year ended 31 March 2024
Revenue from operations		-	-
Other Income	8	403	822
Total income		403	822
Expenses			
Other expenses	9	3,412	1,107
Total expenses		3,412	1,107
(Loss)/ profit before tax		(3,009)	(285)
Tax expense			
- Current tax		-	-
- Deferred tax		-	-
Total tax expense		-	-
(Loss)/ profit for the year		(3,009)	(285)
Other comprehensive income			
Items that will be reclassified to profit or loss			
Exchange differences on translation of foreign operations		-	-
Other comprehensive income for the year, net of tax		-	-
Total comprehensive (loss)/ income/(loss) for the year		(3,009)	(285)



Shyam Pattabiraman
CFO

Place: New Jersey
Date: 12 May 2025

Syed Kazmi
CEO



Place: New Jersey
Date: 12 May 2025

Jubilant Prodel LLC
Statement of changes in equity for the year ended 31 March 2025

A) Equity share capital

	USD
Balance as at 31 March 2023	5,841,317
Additions during the year	1,910,000
Balance as at 31 March 2024	7,751,317
Additions during the year	35,000
Balance as at 31 March 2025	7,786,317

B) Other equity

	USD	
	Reserves and Surplus	
	Retained earnings	Total
Balances as at 31 March 2023	307,491	307,491
Total comprehensive loss for the year	285	285
Balances as at 31 March 2025	307,775	307,775
Total comprehensive loss for the year	3,009	3,009
Balances as at 31 March 2026	310,786	310,786

Shyam Pattabiraman
CFO



Place: New Jersey
Date: 12 May 2025

Syed Kazmi
CEO



Place: New Jersey
Date: 12 May 2025

Jubilant Prodel LLC

Statement of Cash Flows for the year ended 31 March 2025

	USD	USD
	For the year ended 31 March 2025	For the year ended 31 March 2024
A. Cash flow from operating activities		
Profit/(Loss) before tax	(3,009)	(285)
Operating cash flow before working capital changes	(3,009)	(285)
Decrease/(Increase) in trade and other receivables	1,519	52,243
Increase/ (Decrease) in trade payables, provisions and other liabilities	8,599	(633,794)
Cash generated from/(used in) operations	7,109	(581,837)
Income tax and wealth tax paid (net of refund)	-	-
Net cash generated from/(used in) operating activities	7,109	(581,837)
B. Cash flow from investing activities		
Purchase of intangible assets (including capital work-in-progress and intangible asset under development)	(45,687)	(347,761)
Net cash used in investing activities	(45,687)	(347,761)
C. Cash flow arising from financing activities		
Proceeds from issuance of equity	35,000	910,000
Net cash generated from financing activities	35,000	910,000
D. Effect of exchange rate changes		-
Net (decrease)/increase in cash and cash equivalents (A+B+C+D)	(3,579)	(19,598)
Add: cash and cash equivalents at the beginning of year	3,959	23,557
Cash and cash equivalents at the end of the year	381	3,959



Shyam Pattabiraman
CFO

Place: New Jersey
Date: 12 May 2025

Syed Kazmi
CEO



Place: New Jersey
Date: 12 May 2025

Jubilant Prodel LLC**Notes to the financial statements for the year ended 31 March 2025****1. Corporate information**

Jubilant Prodel LLC. ("the Company") was incorporated in United States of America under the local laws of Delaware on 19 February 2019. The Company is a fully owned subsidiary of Jubilant Therapeutics India Limited. The Company will focus on the discovery and development of novel drugs for the treatment of cancer in the area of Oncology and

2. Significant accounting policies

This note provides a list of the significant accounting policies adopted in the preparation of these Standalone Financial Statements ("standalone financial statements").

(a) Basis of preparation**(i) Statement of compliance**

These standalone financial statements have been prepared solely for the purpose of submission of Annual Performance Report to the Reserve Bank of India, in accordance with Indian Accounting Standards (Ind AS) issued by the Institute of Chartered Accountants of India (ICAI).

(ii) Historical cost convention

The Standalone financial statements have been prepared under historical cost convention on accrual basis, unless

(b) Functional and presentation currency

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which the entity operates (i.e. the "functional currency"). The functional currency of the Company is U.S. Dollars ("USD"). These financial statements are presented in USD

(c) Current versus non-current classification

The Company presents assets and liabilities in the Standalone Balance Sheet based on current/ non-current

An asset is treated as current when:

- It is expected to be realized or intended to be sold or consumed in normal operating cycle;
- It is held primarily for the purpose of trading;
- It is expected to be realized within twelve months after the reporting period; or
- It is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period

Current assets include the current portion of non-current financial assets.

The Company classifies all other assets as non-current.

A liability is current when:

- It is expected to be settled in normal operating cycle;
- It is held primarily for the purpose of trading;

Place: New Jersey

- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities respectively.

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Company has identified period less than twelve months as its operating cycle for the purpose of current/non-current classification of assets and liabilities.

Jubilant Prodel LLC
Notes to the financial statements for the year ended 31 March 2025

Note 3: Intangible assets under development

	USD	USD
	As at 31 March 2025	As at 31 March 2024
Intangible assets under development	7,565,968	7,520,280
Total Intangible assets under development	7,565,968	7,520,280

Note 4: Cash and cash equivalents

	USD	USD
	As at 31 March 2025	As at 31 March 2025
Balances with banks		
In current accounts	381	3,959
Total cash and cash equivalents	381	3,959

Note 5: Other current assets

	USD	USD
	As at 31 March 2025	As at 31 March 2024
Prepaid expenses	220	1,740
	220	1,740

Note 6: Equity share Capital

	USD	USD
	As at 31 March 2025	As at 31 March 2024
Issued, subscribed and paid up		
Equity shares	7,786,317	7,751,317

- 1) The Company has only one class of shares referred to as equity shares having no par value. Each holder of equity shares is entitled to one vote per share.
2) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company after distribution of all preferential amounts, if any, in proportion to their shareholding. However no such preferential amounts exist currently.
3) The details of shareholders holding more than 5% shares in the Company:

	No of units	As at 31 March 2025 % holding in the class	No of units	As at 31 March 2024 % holding in the class
Name of the Shareholder				
Jubilant Therapeutics Inc	100	100%	100	100%

4) The reconciliation of the number of shares outstanding as at beginning and at end of the reporting period

	No of units	As at 31 March 2025 USD	No of units	As at 31 March 2024 USD
Numbers of units at the beginning of the year	100	7,751,317	100	5,841,317
Add: Units issued during the year		35,000	-	1,910,000
Number of units at the end of the year	100	7,786,317	100	7,751,317

5) Equity shares held by holding company/ultimate holding company is set out below:

Particulars	As at 31 March 2024 No of units	As at 31 March 2023 No of units
Jubilant Therapeutics Inc	100	100

Note 7: Trade payables

	USD	USD
	As at 31 March 2025	As at 31 March 2024
Trade payables	7,483	2,023
Due to related parties	83,554	80,415
Total trade payables	91,038	82,438

Jubilant Prodel LLC**Notes to the financial statements for the year ended 31 March 2025****Note 8: Other Income**

	USD	USD
	As at	As at
	31 March 2025	31 March 2024
Interest Income	403	822
Total other Income	403	822

Note 9: Other expenses

	USD	USD
	As at	As at
	31 March 2025	31 March 2024
Bank charges	3,474	2,859
Exchange (Gain)/ Loss	(62)	(1,751)
Total other expenses	3,412	1,107